CDK Inhibitors Patent Landscape 2009 : Market Research Report

CDK Inhibitors Patent Landscape 2009

Published by: France Innovation Scientifique et Transfert

Published: Oct. 29, 2009 - 83 Pages

METHODOLOGY
INTRODUCTION
1. BRIEF OUTLINE OF THE PIPELINE
2. PROTECTION STRATEGIES: 2.1. Evolution of patent filings over time; 2.2. Priority filings; 2.3.Extensions; 2.4. Analysis of industrial patents over time; 2.5. Study of the granting of US patents; 2.6. Study of the granting of European patents; 2.7. Evolution in the number of applicants
3. TOPOLOGY OF PATENTS IN THE SECTOR: 3.1. Breakdown of patents into classes of CDK inhibitors; 3.2. Breakdown of patents into types of targeted CDK; 3.3. Cross analysis of the categories “classes of CDK inhibitors” and “types of targeted CDK”
4. ANALYSIS OF THE MAIN APPLICANTS: 4.1. Main applicants; 4.2. Filings by main applicants over time; 4.3. Focus on the global strategy of the major industrial applicants; 4.4. Topics protected; 4.5.Collaborations; 4.6. Citations between applicants; 4.7. Emerging applicants
5. ANALYSIS OF THE MAIN INVENTORS: 5.1. Main inventors; 5.2. Topics protected; 5.3. Research teams; 5.4. Experts; 5.5. Emerging inventors
CONCLUSION
APPENDIX 1: APPLICANTS WITH ACTIVE CLINICAL TRIALS AND THEIR
NUMBER OF PATENT FILINGS
APPENDIX 2: PATENT FILINGS OF APPLICANTS BY MAIN TOPICS
APPENDIX 3: NUMBER OF PATENT FILINGS PER APPLICANTS

Abstract

IP Overview presents a patent landscape analysis of the CDK Inhibitor field.

Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative diseases such as renal diseases and cancers. These observations led the CDK family to become a central target for the development of new therapies.

During the last two decades, evolution of patent filings of CDK inhibit ors shows two major phases. A strong increase until 2002 is associated with the capacity of CDK inhibitors to target a large number of diseases. Results of advanced clinical stages confirm the potential of these compounds but emphasize new challenges in order to reach marketable products. A significant decrease follows until 2005 when a new generation of CDK inhibitors takes the lead in R&D interest.

This IP Overview provides you with a comprehensive panorama of the intellectual property landscape of this new and promising sector and helps you:

Position your company’s R&D and IP Portfolio,
Identify key inventors and key players involved in specific thematic,
Understand the collaboration networks and theirs dynamics,
Uncover trends and emerging segments

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 31

CDK Inhibitors Patent Landscape 2009

Table of Contents

Abstract